The striatum plays critical roles in action control and cognition, and activity of striatal neurons is driven by glutamatergic input. Inhibition of glutamatergic inputs to projection neurons and interneurons of the striatum by presynaptic G protein-coupled receptors (GPCRs) stands to modulate striatal output and striatum-dependent behaviors. Despite knowledge that a substantial number of glutamatergic inputs to striatal neurons originate in the thalamus, most electrophysiological studies assessing GPCR modulation do not differentiate between effects on corticostriatal and thalamostriatal transmission, and synaptic inhibition is frequently assumed to be mediated by activation of GPCRs on corticostriatal terminals. We used optogenetic techniques and recently-discovered pharmacological tools to dissect the effects of a prominent presynaptic GPCR, metabotropic glutamate receptor 2 (mGlu 2 ), on corticostriatal vs. thalamostriatal transmission. We found that an agonist of mGlu 2 and mGlu 3 induces long-term depression (LTD) at synapses onto MSNs from both the cortex and the thalamus. Thalamostriatal LTD is selectively blocked by an mGlu 2 -selective negative allosteric modulator and reversed by application of an antagonist following LTD induction. Activation of mGlu 2/3 also induces LTD of thalamostriatal transmission in striatal cholinergic interneurons (CINs), and pharmacological activation of mGlu 2/3 or selective activation of mGlu 2 inhibits CIN-mediated dopamine release evoked by selective stimulation of thalamostriatal inputs. Thus, mGlu 2 activation exerts effects on striatal physiology that extend beyond modulation of corticostriatal synapses, and has the potential to influence cognition and striatum-related disorders via inhibition of thalamus-derived glutamate and dopamine release.
Introduction
The basal ganglia are an interconnected group of subcortical nuclei that play important roles in action control and cognition (Graybiel and Grafton, 2015) . The striatum serves as the major input nucleus of the basal ganglia, and striatal activity is driven by glutamatergic inputs to medium spiny projection neurons (MSNs, the principal cell type in the striatum) from various cortical regions as well as the thalamus (Alexander et al., 1986; Hintiryan et al., 2016; Smith et al., 2014) . This glutamatergic transmission is the main stimulus that drives action potentials in the otherwise passive MSNs, and thus glutamatergic synapses are key points for modulation of striatal function. The striatum is also densely innervated by midbrain dopamine neurons, which modulate a variety of physiological processes and are critical for behaviors including movement, acquisition of motor skills, and instrumental learning (Baik, 2013; Beeler et al., 2014) . Substantial effort has been made to understand the physiology of corticostriatal circuits and how they impact behavior. However, despite the abundance of thalamic synapses in the striatum, our understanding of the thalamostriatal system remains limited. Thalamostriatal projections are thought to relay information about salient sensory stimuli and environmental context to regulate behaviors such as attentional shifting, behavioral switching, and reinforcement of instrumental learning (Bradfield et al., 2013; Smith et al., 2011) . In addition to regulating striatal output by directly exciting MSNs and indirectly gating corticostriatal transmission (Ding et al., 2010; Smith et al., 2014) , thalamostriatal inputs also modulate striatal function by facilitating dopamine release via activation of cholinergic interneurons (CINs) (Threlfell et al., 2012) . Although modest progress has been made in elucidating functional roles of thalamostriatal circuits in recent years, many questions remain about the physiology of thalamic inputs to the striatum and their roles in striatal function. For example, little is known about how G protein-coupled receptors (GPCRs) modulate thalamostriatal transmission to influence striatal physiology.
Among the GPCRs that modulate striatal glutamatergic transmission are the metabotropic glutamate (mGlu) receptors. The eight subtypes of mGlu receptors represent three distinct groups (Niswender and Conn, 2010) , each of which is known to impact excitatory transmission in the striatum. Group I mGlu receptors (mGlu 1 and mGlu 5 ) are expressed postsynaptically in the striatum and contribute to long-term regulation of excitatory transmission by promoting retrograde endocannabinoid signaling (Kreitzer and Malenka, 2005; Sung et al., 2001; Wu et al., 2015) . Group II mGlu receptors (mGlu 2 and mGlu 3 ) and group III mGlu receptors (mGlu 4 , -7 , -8 ) act as presynaptic autoreceptors in the striatum (Johnson and Conn, 2012) . Electrophysiological recordings in rodent striatal slices have revealed that group II mGlu receptor-selective agonists reduce excitatory transmission, with some reports of transient depression (Lovinger and McCool, 1995; Martella et al., 2009 ) and other demonstrations of long-term depression (LTD) (Kahn et al., 2001; Kupferschmidt and Lovinger, 2015) . Until recently, identification of the specific receptor subtypes that regulate striatal excitatory transmission proved challenging due to a lack of subtype-selective ligands for group II and III mGlu receptors, although one recent study demonstrated that inhibition of evoked field potentials by an mGlu 2/3 agonist was absent in mice lacking mGlu 2 (Zhou et al., 2013) , demonstrating a critical role for this receptor. Robust expression of both mGlu 2 and mGlu 3 has been described in the striatum (Wright et al., 2013) , and mGlu 2 expression is likely to be restricted primarily to afferents to the striatum, as little evidence for mGlu 2 mRNA has been found within the striatum (Ohishi et al., 1993; Testa et al., 1994) . Interestingly, mGlu 2 mRNA is detected throughout the cortex as well as in the intralaminar nuclei of the thalamus (Allen Brain Atlas; www.brain-map.org), suggesting that mGlu 2 activation could modulate transmission in both striatal inputs. mGlu 3 mRNA is also present in the cortex and thalamus, and potential contributions of mGlu 3 to regulation of excitatory transmission in the striatum have not been directly evaluated.
The majority of previous studies examining modulation of striatal glutamatergic transmission by GPCRs such as mGlu 2/3 employed electrical stimulation either within the striatum or in the overlying white matter. Because cortical and thalamic inputs innervate the same cells (Doig et al., 2010; Huerta-Ocampo et al., 2014) , the input specificity of GPCR modulation could not be determined using such techniques, yet inhibition of striatal glutamatergic transmission was often assumed to represent regulation of neurotransmitter release at corticostriatal terminals. To circumvent this shortcoming, we implemented both transgenic and viral techniques to express channelrhodopsin-2 (ChR2) in corticostriatal or thalamostriatal projection neurons and evaluated the ability of group II mGlu receptor activation to reduce glutamate release from each input. Using recently discovered subtypeselective pharmacological tools, we now demonstrate that mGlu 2 activation induces robust LTD of thalamostriatal transmission in both MSNs and CINs of the dorsal striatum. In addition, an mGlu 2/3 agonist reduces phasic dopamine release that is specifically mediated by thalamostriatal activation of CINs. These findings advance our limited understanding of how presynaptic autoreceptors regulate discrete aspects of striatal physiology.
Methods
Animals. Animal care and procedures used for these studies were approved by the Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism and conformed to the guidelines of the US National Institutes of Health Guide for the Care and Use of Animals. For most experiments, 9e18 week old male C57Bl/6J mice (The Jackson Laboratory, stock no. 000664) were used. For experiments evaluating glutamatergic transmission in CINs, hemizygous ChAT-IRES-Cre mice (The Jackson Laboratory, stock no. 006410) were crossed with Ai14 mice (The Jackson Laboratory, stock no. 007908) to drive TdTomato reporter expression in CINs. For some experiments evaluating corticostriatal and thalamostriatal transmission, Ai32 mice (The Jackson Laboratory, stock no. 024109) were crossed with Emx1-IRES-Cre (The Jackson Laboratory, stock no. 005628) or vGlut2-IRES-Cre mice (The Jackson Laboratory, stock no. 016963, backcrossed at NIAAA to C57Bl/6J mice for at least six generations), respectively. This allowed Credependent expression of ChR2 in the striatal inputs of interest. Animals were housed 2e4 per cage in a temperature-and humidity-controlled room with a standard 12 h light/dark cycle and ad libitum access to food and water.
Viral injections for optogenetics experiments. Male C57Bl/6J mice and male or female ChAT-IRES-Cre; Ai14 mice (5e8 weeks old) were anesthetized with isoflurane (5% induction,~2% maintenance) and placed into a stereotaxic frame (David Kopf Instruments). Mice were injected with 250e300 nL AAV1.CamKIIa.hChR2(H134R)-eYFP (University of Pennsylvania Vector Core) at a rate of 75 nL/min using a Hamilton syringe. For recordings of corticostriatal transmission, injections were targeted to M1 motor cortex (coordinates relative to bregma: 1.1 anterior; ±1.6 lateral; 0.8 ventral from brain surface). For recordings of thalamostriatal transmission, injections were targeted to the parafascicular nucleus (coordinates relative to bregma: À2.1 posterior; ±0.6 lateral, 3.8 ventral from brain surface). Brain slices were prepared for electrophysiology or FSCV recording 4e10 weeks following surgery. Verification of injection sites and imaging of eYFP fluorescence were performed on an Olympus MVX10 microscope (Olympus Corporation of America).
Brain slice preparation for electrophysiology and fast-scan cyclic voltammetry. Coronal brain slices (250 mm thick) were prepared using a vibratome (Leica Microsystems) as previously described (Atwood et al., 2014a; Crowley et al., 2014; Mathur et al., 2011) . Mice were anesthetized with isoflurane, decapitated, and brains were rapidly removed and submerged in ice-cold cutting solution containing (in mM): 30 NaCl, 4.5 KCl, 1 MgCl 2 , 26 NaHCO 3 , 1.2 NaH 2 PO 4 , 10 glucose, and 194 sucrose, continuously bubbled with 95% O 2 /5% CO 2 . Slices were immediately removed to a 32 C holding chamber containing artificial cerebrospinal fluid (aCSF) containing (in mM): 124 NaCl, 4.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 26 NaHCO 3 , 1.2 NaH 2 PO 4 , and 10 glucose, 305e310 mOsm, continuously bubbled with 95% O 2 /5% CO 2 . Slices were allowed to recover for 30e45 min at 32 C, and then were incubated at room temperature for at least 30 min prior to beginning experiments. Whole-cell voltage clamp recordings. Whole-cell voltage-clamp recordings were conducted as previously described (Atwood et al., 2014a) . Individual hemisected slices were placed in a diamondshaped recording chamber (Warner Instruments) and were submerged in, and continuously perfused with 30e32 C aCSF at a rate of~1.5 mL/min. Recording pipettes (2.0e4.0 MU resistance in bath) were filled with Cs-based internal solution (295e300 mOsm) containing (in mM): 120 CsMeSO 3 , 5 NaCl, 10 TEA-Cl, 10 HEPES, 5 QX-314, 1.1 EGTA, 0.3 Na-GTP, and 4 Mg-ATP; pH was adjusted to 7.3 using CsOH. Slices were visualized on a Zeiss Axioskop 2 microscope. Cells for whole-cell recordings were visualized using a 40x/ 0.8 NA water-immersion objective. Putative MSNs were identified based on size, capacitance, and membrane resistance. CINs were identified by online visualization of the fluorescent reporter. Recordings were performed using a Multiclamp 700 A amplifier (Axon Instruments). Cells were voltage-clamped at À60 mV throughout the experiment. For electrically-evoked excitatory postsynaptic current (eEPSC) recordings, a parallel bipolar stimulating electrode (~100 mm tip separation) was positioned at the border of the external capsule and the dorsolateral striatum. Cells were recorded within the dorsolateral striatum. For optically-evoked EPSC (oEPSC) recordings, 470 nm, 2e5 ms pulse-width field illumination was delivered via a High-Power LED Source (Thor Labs). For both electrically-evoked and optically-evoked EPSC recordings, stimulation intensity was typically adjusted to elicit 150e500 pA current amplitudes. Electrically-evoked EPSCs were evoked every 20 s, and optically-evoked EPSCs were evoked once per minute. For pairedpulse EPSC recordings, a 50 ms interpulse interval was used. All recordings were filtered at 2 kHz and digitized at 10 kHz (Digidata 1322A, Axon Instruments). For all EPSC recordings, 50 mM picrotoxin was included in the aCSF to block fast GABAergic transmission. Drugs were prepared as stock solutions in water or dimethylsulfoxide (DMSO) and diluted into aCSF prior to each experiment. For experiments using drugs prepared in DMSO, the DMSO concentration was held constant throughout the experiment, with a maximum of 0.1% final DMSO concentration. Drugs were administered via bath application for the designated period of time; antagonists were present throughout the recording. Acquisition was performed using Clamplex 10.3 (Molecular Devices). Access resistance was monitored during recordings and only cells with a stable access resistance (less than 15% change from baseline) were included for analysis.
Fast-scan cyclic voltammetry (FSCV) recordings. A glass-encased cylindrical carbon fiber (Goodfellow, PA; 7 mm diameter, 100e130 mm exposed length) was placed into the DLS at a location expressing eYFP. Optical stimulation was delivered by placing an optical fiber (105 mm core diameter, 0.22 NA, Thorlabs, NJ) in apposition to the brain slice. Extracellular dopamine release was monitored by FSCV by applying a triangular input waveform from À0.4 V to þ1.2 V and back to À0.4 V (versus an Ag/AgCl reference electrode immersed in the bath solution) through the carbon fiber electrode. Cyclic voltammograms were collected at 10 Hz using a Chem-Clamp (Dagan Corporation) and DEMON Voltammetry and Analysis software (Yorgason et al., 2011) . Once five consecutive stable responses were collected (<10% variation in transient peak), experiments would begin. Four baseline measurements were collected before bath application for 10 min of LY379268 (100 nM). Following drug application, four extra drugwashout measurements were collected. Drugs. Picrotoxin and QX-314 were purchased from Sigma. LY379268, LY395756, and LY341495 were purchased from Tocris Bioscience. VU6001192 and VU0469942 were generously provided by the Vanderbilt Center for Neuroscience Drug Discovery (Vanderbilt University, Nashville, TN).
Data analysis and statistics. EPSC amplitudes were measured using Clampfit 10 software (Molecular Devices). GraphPad Prism 6.0 was used to prepare graphs and perform statistical analyses. All data are reported as mean ± SEM. For electrically-evoked EPSC recordings, amplitudes were averaged each minute. EPSC data were normalized to the average EPSC amplitudes during a 10 min baseline recording. PPRs were calculated by dividing the amplitude of the second EPSC by the amplitude of the first EPSC. PPR comparisons were made for a 5 min window before and after drug treatment (6e10 min post-drug, during peak drug effect) using a paired t-test. Peak drug effects were measured at 6e10 min after the onset (f) Summary of LY379268 effect from 6 to 10 min after onset of LY379268 application (mean ± SEM). VU6001192 significantly blocked the effect of LY379268 (control vs. VU6001192, p < 0.05, Dunnett's test). EPSC amplitude time course data are normalized to the average baseline EPSC amplitude and shown as mean ± SEM. of drug application unless otherwise indicated. LTD was measured at 25e30 min after onset of drug application unless otherwise indicated. Sample traces and % baseline values reported in the text correspond to these time windows. N values represent the number of recorded cells. One experiment was performed on each slice, and slices were always drug-naïve prior to experiments. Each dataset contains experiments obtained from at least 2 animals. Withingroup comparisons of drug effects vs. baseline were made using paired t tests. Comparisons of peak depression or LTD magnitude between groups were made using an unpaired t-test or a one-way ANOVA followed by post-hoc Dunnett's comparison with control. Alpha was set at 0.05.
Results

Presynaptic mGlu 2 activation induces LTD of electrically-evoked glutamate transmission in the DLS
Previous studies have demonstrated that various mGlu 2/3 agonists depress excitatory transmission evoked by electrical stimulation in the dorsal striatum. However, discrepancies exist regarding whether this depression represents short-or long-term changes in neurotransmitter release (for example, see Kahn et al., 2001; Kupferschmidt and Lovinger, 2015; Lovinger and McCool, 1995; Martella et al., 2009 ). We performed whole-cell voltage clamp recordings of electrically-evoked EPSCs from MSNs in the DLS to determine the effect of the mGlu 2/3 -selective agonist LY379268 on glutamatergic transmission. After recording stable EPSC amplitudes for at least 10 min, LY379268 (100 nM) was bathapplied to slices for 5 min. This produced a substantial, long-lasting depression of eEPSC amplitudes (52.8± 5.8% of baseline; n ¼ 10; p < 0.0001) (Fig. 1a) that began during agonist application. The depression persisted for at least 30 min after the termination of drug application in 9/10 cells. Reduction of eEPSC amplitude was associated with a significant increase in paired-pulse ratios (mean EPSC2/EPSC1 amplitude: baseline, 1.19 ± 0.09 vs. post-drug 1.55 ± 0.11; n ¼ 9; p ¼ 0.037) (Fig. 1b and c) , indicating that LY379268 treatment is associated with a decreased probability of glutamate release. Although LY379268-mediated depression of electrically-evoked field potentials was previously shown to require mGlu 2 (Zhou et al., 2013) , pharmacological analysis of the individual contributions of mGlu 2 and mGlu 3 has not been reported. To directly evaluate the role of each receptor in nontransgenic mice, we used two recently reported negative allosteric modulators (NAMs), VU6001192 and VU0469942, which are selective for mGlu 2 and mGlu 3 , respectively (Felts et al., 2015; Wenthur et al., 2013) . Incubation of slices with VU6001192 (10 mM, present throughout recording) completely prevented the LY379268-mediated depression of eEPSC amplitude (control 50.0± 8.2% of baseline, n ¼ 10, vs. VU6001192 99.7± 11.0% of baseline, n ¼ 6, at 6e10 min following onset of LY379268 application), whereas VU0469942 (10 mM, present throughout recording) did not block the effect of LY379268 (56.6± 4.6% of baseline; n ¼ 6) (Fig. 1def) . One-way ANOVA revealed a main effect of antagonist treatment (F (2, 19) ¼ 8.761; p ¼ 0.002) (Fig. 1f) . Post hoc Dunnett's comparison showed a significant blockade by VU6001192, but not VU0469942, when compared with the LY379268-mediated depression of eEPSC amplitude in control slices (Fig. 1f) . These results indicate that mGlu 2 mediates the depression of excitatory transmission that is broadly evoked by electrical stimulation, and that mGlu 3 is unlikely to play a role.
mGlu 2/3 activation depresses corticostriatal transmission
Previous studies of mGlu 2/3 agonist effects on electricallyevoked excitatory transmission in the dorsal striatum have generated the prevailing idea that mGlu 2 activation produces a depression of corticostriatal transmission. However, none of these studies used techniques that could distinguish modulation of corticostriatal vs. thalamostriatal transmission. To directly evaluate this, we injected an adeno-associated viral (AAV) vector encoding ChR2-EYFP under the control of the CamKIIa promoter into the M1 motor cortex region of C57Bl/6J mice. Four to ten weeks after injection, EYFP-labeled axon terminals were visible in the dorsolateral striatum (Fig. 2a) . We recorded optically-evoked EPSCs from MSNs within the DLS and found that 5 min bath application of LY379268 (100 nM) produced robust LTD (33.3± 6.2% of baseline; n ¼ 6; p < 0.001) (Fig. 2b) . To evaluate the effect of mGlu 2/3 activation on a broader set of cortical inputs, we crossed Ai32 mice, which express ChR2 in a Cre recombinase-dependent manner (Madisen et al., 2012) , with Emx1-Cre mice, which express Cre recombinase in glutamatergic projection neurons of the cortex and hippocampus (Gorski et al., 2002; Kupferschmidt and Lovinger, 2015) . This produced Emx1-Cre;Ai32 mice with ChR2 specifically expressed in cortical inputs to the striatum. Recordings of oEPSCs from MSNs of Emx1-Cre;Ai32 mice revealed that 5 min bath application of LY379268 (100 nM) produced a significant reduction of oEPSC amplitude (69.1± 6.4% of baseline; n ¼ 11; p ¼ 0.002) (Fig. 2c) . Interestingly, the magnitude of LY379268-mediated depression was significantly greater in M1 virus-injected mice than in Emx1-Cre;Ai32 mice (p ¼ 0.0024) (Fig. 2d) . To ensure that this result was not due to a general reduction in mGlu 2/3 function in Emx1-Cre;Ai32 mice, we performed several recordings in which we interleaved electrical and optical stimulation. In these recordings, LY379268 routinely produced a greater inhibition of electricallyevoked stimulation than optically-evoked stimulation, suggesting that the lower magnitude of the LY379268 effect in the Emx1-Cre;Ai32 mice was specific to corticostriatal inputs activated by optical stimulation (data not shown). Together, these results provide direct evidence that an mGlu 2/3 agonist induces LTD at corticostriatal synapses.
mGlu 2 activation produces a reversible form of LTD at thalamostriatal synapses
Whereas GPCR-mediated modulation of corticostriatal transmission has received a great deal of attention in the literature, few studies have examined modulation of thalamostriatal transmission. To assess the potential regulation of thalamostriatal transmission by group II mGlu receptors, we virally expressed ChR2 via injections targeting the parafascicular nucleus of the thalamus, which provides a major input to the dorsal striatum (Smith et al., 2014) . Four to ten weeks after injection, we observed diffuse EYFP-labeled axon terminals throughout the striatum (Fig. 3a) , including in the DLS. We recorded oEPSCs from MSNs in the DLS and found that 5 min bath application of LY379268 (100 nM) produced LTD that persisted for at least 30 min following the onset of drug application (39.3± 6.2% of baseline; n ¼ 8; p < 0.0001) (Fig. 3b) . As an alternative approach, we crossed Ai32 mice with Vglut2-Cre mice to obtain Vglut2-Cre;Ai32 mice. In accordance with previously identified Vglut2 expression patterns, these mice express Cre recombinase in the thalamus and not in striatumprojecting cortical neurons (Fremeau et al., 2004; Vong et al., 2011) . As with virus-injected mice, LY379268 (100 nM, 5 min) induced LTD in DLS MSNs of Vglut2-Cre;Ai32 mice (42.0± 5.4% of baseline; n ¼ 10; p < 0.0001) (Fig. 3c) . There was no difference in the magnitude of LTD induced by LY379268 when using the two different methods of ChR2 expression (p ¼ 0.75) (Fig. 3d) . Together, these results provide the first direct evidence that in addition to the widely-accepted regulation of corticostriatal transmission, activation of group II mGlu receptors strongly modulates striatal glutamatergic transmission arising from the thalamus.
We next used subtype-selective pharmacological tools to explicitly test the roles of mGlu 2 and mGlu 3 on thalamostriatal transmission in mice virally expressing ChR2 in the parafascicular nucleus. We recorded the effect of LY379268 (100 nM, 5 min) in the presence of the group II mGlu receptor-preferring antagonist LY341495 (500 nM) (Fig. 4c) , the mGlu 2 -selective NAM VU6001192 (10 mM, Fig. 4a,c) , or the mGlu 3 -selective NAM VU0469942 (10 mM, Fig. 4b and c) . One-way ANOVA revealed a significant effect of antagonist treatment (F (3, 23) ¼ 13.57, p < 0.0001). Post hoc analysis revealed that both LY341495 and VU6001192 significantly reduced the effect of LY379268 when compared with control slices (control 57.5± 3.6% of baseline, n ¼ 7; LY341495 107.1± 8.9% of baseline, n ¼ 7; VU6001192 85.0± 6.1% of baseline, n ¼ 6; 6e10 min following onset of drug application) (Fig. 4a,c) , whereas VU0469942 had no effect (51.3± 8.2% of baseline, n ¼ 7) (Fig. 4b and c) . Concordant with our observations of electrically-evoked stimulation, our results suggest that mGlu 2 exclusively regulates thalamostriatal transmission.
A common feature of mGlu receptor-mediated LTD is that antagonist application following induction of LTD restores baseline levels of synaptic transmission . To test the reversibility of mGlu 2 -LTD of thalamostriatal transmission, we induced LTD with LY379268 (100 nM, 5 min), then applied the mGlu 2/3 -preferring antagonist LY341495 (500 nM) to slices from 10 to 20 min following the onset of LY379268 application. Similar to previous reports (Kupferschmidt and Lovinger, 2015) , we found that mGlu 2 -LTD was indeed reversible upon subsequent antagonist exposure (Fig. 4d) . This is unlikely to be caused by incomplete washout of LY379268, as this drug is known to produce reversible effects in similar preparations (for example, Walker et al., 2015) . Unlike several reports of "reversibly reversible" antagonist effects on mGlu receptor-mediated LTD , we did not observe restoration of depressed transmission after washout of LY341495 (Fig. 4d) . To further assess the ability of mGlu 2 to modulate excitatory transmission, we examined the effect of LY395756 (10 mM), an mGlu 2 partial agonist that also blocks mGlu 3 responses at higher concentrations (Dominguez et al., 2005; Hanna et al., 2013; Sanger et al., 2013) , on both electrically-evoked EPSCs and opticallyevoked thalamostriatal EPSCs. Surprisingly, five minute bath application of LY395756 produced a striking but reversible inhibition of both electrically-evoked (Fig. 5a ) and optically-evoked (Fig. 5b ) EPSCs (electrically-evoked: 33.4± 5.9% of baseline at 4e6 min following onset of drug application, n ¼ 6, p < 0.001; optically-evoked: 28.0± 4.2% of baseline, n ¼ 6, p < 0.0001). It is unlikely that the concentration of LY395756 used was insufficient to induce LTD given the remarkable magnitude of the acute depression and previous reports that this drug induces LTD at other synapses at lower concentrations . These findings further support the role of mGlu 2 in modulating thalamostriatal transmission, but also demonstrate that ligands with distinct pharmacological profiles (i.e. full vs. partial agonist) can produce different forms of synaptic modulation.
mGlu 2 modulates thalamically-driven dopamine release mediated by cholinergic interneuron activation
Because thalamostriatal inputs to CINs are important regulators of striatum-dependent learning (Bradfield et al., 2013) , we proceeded to test the impact of mGlu 2/3 activation on thalamic inputs to CINs. We performed whole-cell recordings of optically-evoked EPSCs from CINs of ChAT-Cre;Ai14 mice virally expressing ChR2 in thalamic inputs to the striatum. ChAT-Cre;Ai14 mice express the fluorescent reporter TdTomato in CINs, allowing online visual identification of CINs. Five minute bath application of LY379268 (100 nM) induced robust LTD of thalamostriatal transmission (46.8± 5.6% of baseline; n ¼ 6; p < 0.0001) (Fig. 6a) . Thalamostriatal activation of CINs is known to drive dopamine release in the dorsal striatum (Threlfell et al., 2012) , so we next assessed the ability of mGlu 2/3 activation to reduce dopamine release evoked by optical stimulation of thalamostriatal inputs using FSCV in brain slices. Comparable to effects on excitatory transmission in CINs, we found that LY379268 (100 nM, 10 min) produced a substantial reduction of dopamine release (43.2± 10.4% of baseline upon termination of drug application; baseline [DA] 0.96 ± 0.20 mM vs. LY379268 0.37 ± 0.13 mM; n ¼ 6; p ¼ 0.0275) (Fig. 6b and c) . To directly evaluate the role of mGlu 2 in the inhibition of dopamine release, we applied LY395756 (10 mM, 10 min) to slices and found that this drug also robustly reduced dopamine release (61.0± 3.2% of baseline upon termination of drug application; baseline [DA] 0.49 ± 0.08 mM vs. LY395756 0.29 ± 0.05 mM; n ¼ 6; p ¼ 0.0035) (Fig. 6d) , indicating a specific role for mGlu 2 in the regulation of thalamically-driven dopamine release.
Discussion
We employed optogenetic techniques to dissect circuit-specific modulation of striatal excitatory transmission by mGlu 2 . Recently, our laboratory and others have used similar approaches to distinguish roles of opioid, cannabinoid, and histamine receptors in regulating corticostriatal vs. thalamostriatal transmission (Atwood et al., 2014a; Ellender et al., 2011; Wu et al., 2015) . Indeed, for each of these receptor classes, differential modulation of corticostriatal vs. thalamostriatal transmission has been reported. Interestingly, mGlu 2 appears to be the first example of a GPCR that modulates both synapses to a similar extent. However, because cortical and thalamic synapses have distinct properties, such as differences in short-term plasticity, basal probability of glutamate release, and postsynaptic ionotropic glutamate receptor composition (Ding et al., 2008; Smeal et al., 2008) , it is possible that activation of mGlu 2 in each pathway yields differential effects on striatal output. Intriguingly, we observed a substantial divergence in the magnitude of LTD when recording inputs from the motor cortex vs. broadly activating cortical inputs in the Emx1-Cre;Ai32 mouse (Fig. 2bed) . This finding suggests that striatal inputs from distinct cortical regions are differentially regulated by mGlu 2 activation. Further studies evaluating modulation of discrete corticostriatal inputs will be necessary to elucidate the role of mGlu 2 in various circuits that impact different aspects of basal ganglia-related behaviors.
Both cortical and thalamic inputs to the striatum drive phasic dopamine release by activating CINs and releasing acetylcholine, which evokes dopamine release by activating presynaptic nicotinic receptors on dopamine terminals (Cachope et al., 2012; Kosillo et al., 2016; Threlfell et al., 2012) . Thus, it stands to reason that mGlu 2 activation could regulate dopamine release. We report that activation of mGlu 2 inhibits dopamine release evoked by optogenetic activation of thalamic inputs to the striatum (Fig. 6bed) . This finding is in agreement with results of microdialyisis studies in the ventral striatum which suggest that group II mGlu receptors tonically reduce extracellular dopamine levels (Baker et al., 2002; Hu et al., 1999) . However, more recent microdialysis studies failed to observe a decrease in dorsal striatal dopamine release evoked by in vivo electrical stimulation of midbrain dopamine neurons (Pehrson and Moghaddam, 2010) , suggesting that mGlu 2 does not modulate dopamine release by acting as a heteroreceptor on dopaminergic axon terminals. The ability of LY379268 to robustly depress thalamostriatal transmission in CINs (Fig. 6a) suggests that mGlu 2 on thalamostriatal terminals mediates the inhibition of thalamically-driven dopamine release, although an additional role for mGlu 2/3 activation on CIN terminals cannot be ruled out (Marti et al., 2001) .
We found that mGlu 2 -mediated depression of thalamostriatal transmission is both long-lasting and reversible upon application of a competitive antagonist following LTD induction (Figs. 3 and 4d) . Thus, this represents a "labile" form of GPCR-mediated LTD, a phenomenon which is commonly observed across all groups of mGlu receptors (Atwood et al., 2014b; Lodge et al., 2013) . Discrepancies exist in the literature regarding whether or not the depression of electrically-evoked excitatory transmission by mGlu 2/3 activation is transient or represents a form of agonistinduced LTD. These inconsistent findings may result from technical differences, the agonist used in the study, or the species, as reversible inhibition has been reported in rats (Lovinger and McCool, 1995; Picconi et al., 2002) , whereas LTD has commonly been observed in mice (Kahn et al., 2001; Kupferschmidt and Lovinger, 2015; Zhou et al., 2013) . In addition, previous data suggested that mGlu 2 -mediated LTD in the striatum was not affected by subsequent antagonist application (Kahn et al., 2001) , whereas this and other reports from our laboratory indicate that presynaptic mGlu 2 effects in the mouse striatum represent labile forms of LTD (Kupferschmidt and Lovinger, 2015) . Although it remains unclear how mGlu receptors continue to signal long after agonist washout, the prevailing hypothesis is that the receptors adopt a constitutively active conformation that allows agonist-independent activity but remains sensitive to antagonist treatment Young et al., 2013) . The continued development of techniques to examine nuanced changes in receptor structure during and following ligand-binding could provide critical insight into the mechanisms by which mGlu receptors mediate flexible forms of synaptic plasticity.
A particularly intriguing finding of our study was that the mGlu 2 partial agonist/mGlu 3 antagonist LY395756 produces a transient rather than a long-term form of synaptic inhibition (Fig. 5) . Several explanations might account for the differential efficacy of LY379268 vs. LY395756. One interpretation of this finding is that mGlu 3 activation is required for the long-term component of the LY379268 effect, and in fact this has been demonstrated in the medial prefrontal cortex (Walker et al., 2015) . However, our finding that the mGlu 3 NAM VU0469942 fails to convert the LY379268 effect from LTD to a reversible form of synaptic depression is inconsistent with this interpretation (Figs. 1e and 4c ). Another possibility is that the efficacy of LY395756 is insufficient to induce LTD; this notion is supported by a recent report that the active enantiomer, LY541850, is a partial agonist in primary neuron cultures, although the efficacy of this drug may be context dependent (i.e. dependent on levels of receptor reserve) Sanger et al., 2013) . Given the strikingly robust acute inhibition produced by LY395756 (Fig. 5) , this explanation also seems unlikely. A third possibility is that LY395756 acts as a functionally biased agonist such that mechanisms that mediate short-term reductions in glutamate release probability are preferentially engaged over the signaling pathways required for induction of LTD. Additional insight into the mechanistic underpinnings of presynaptic LTD will be necessary to further explore this possibility. Our demonstration of the inconsistent effects of structurally similar agonists highlights the importance of considering nuanced characteristics of pharmacological tools when interrogating GPCR function in native systems.
Modulation of glutamatergic transmission by striatal group II mGlu receptors is altered in a number of animal models of CNS disorders. For example, striatal dopamine denervation by 6-hydroxydopamine lesion produces an increase in the potency with which LY379268 depresses electrically-evoked excitatory transmission (Picconi et al., 2002) . Similarly, enhanced sensitivity to LY379268 was reported in multiple genetic models of Parkinson's disease (Martella et al., 2009 ). Conversely, reduced mGlu 2/3 function has been observed in models of alcohol dependence and cocaine self-administration (Baker et al., 2003; Meinhardt et al., 2013) . The potential involvement of these receptors in behavioral alterations associated with pathological conditions provides compelling reasons to elucidate their input-specific functions in both normal and pathological states. Identification of discrete circuits that experience changes in neuromodulation will advance our understanding of the neurobiology of CNS disorders and provide insight into how aberrant circuit function produces pathological behaviors. However, a thorough understanding of receptor function under normal conditions is necessary to interpret effects of diseaserelevant manipulations. In addition, knowledge of how presynaptic GPCRs such as mGlu 2 modulate circuits that are involved in specific CNS disorders facilitates identification of therapeutic targets. Indeed, agonists and positive allosteric modulators of mGlu 2 have entered clinical trials in recent years for treatment of striatumrelated disorders including addiction and schizophrenia (Cross, 2013; Patil et al., 2007; Salih et al., 2015) , and enhancing our understanding of how these drugs affect relevant circuits within the context of a particular disorder could facilitate predictions regarding their efficacy for particular symptom-related endpoints.
In conclusion, we have used optogenetic techniques to demonstrate that mGlu 2 -mediated inhibition of striatal excitatory transmission, a phenomenon which has long been attributed to activation of presynaptic receptors on cortical afferents, occurs similarly at both corticostriatal and thalamostriatal inputs. Use of this approach will likely be advantageous when considering the routine functions and therapeutic applications of specific presynaptic GPCRs, as it provides refined information about how discrete circuits are modulated. As our understanding of how individual circuits contribute to normal and disease-related behaviors increases, we will likely see a substantial improvement in our ability to predict how pharmacological manipulation of GPCRs will impact behavior and alleviate symptoms of CNS disorders. This is especially important given the fact that drugs targeted at GPCRs, including presynaptic GPCRs, are among the most widely used therapeutic agents.
